Comparing atogepant, topiramate and propranolol for preventing migraine
Compares atogepant, topiramate and propranolol for migraine prevention in adults.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Aurora, Burlington, Charlotte, Columbus, Edison, Flagstaff, Hazel Green, Hollywood, Hyde Park, Indianapolis, Jacksonville, Kingston, Los Angeles, Manhasset, Marshfield, McAllen, Miami, Milwaukee, Morgantown, Nashville, New York, Ogden, Omaha, Overland Park, Palm Springs, Philadelphia, Phoenix, Pomona, Portland, Providence, Reno, Rochester, Salisbury, St Louis, and Winston-Salem, United StatesSee the 39 sites
- Trial code
- Registry title
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 1,335 people, planned
- Started
- 9 Jul 2025
- Expected to end
- 1 Dec 2029
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Atogepant 60 mg
- Propranolol 160 mg
- Topiramate 100 mg
- Record updated
- 13 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with migraine who have at least four moderate to severe headache days a month. It compares three preventive medicines.
- Age
- 18 to 70 years
- Sex
- All sexes
- Disease stage
- Migraine with aura, migraine without aura, and/or chronic migraine (ICHD-3 criteria). Migraine started before age 50 and has lasted at least 12 months. At least four moderate to severe headache days per month.
- Earlier treatment
- People already on a migraine preventive treatment must keep it unchanged for the first 16 weeks. Cannot have started or changed a preventive in the 12 weeks before enrolment. Cannot have taken atogepant, propranolol or topiramate before (occasional as-needed propranolol is fine).
Main reasons for not taking part
- Migraine with brainstem aura, hemiplegic migraine, retinal migraine, or pure menstrual migraine
- Current or past epilepsy
- Severe liver problems or moderate or worse kidney problems
- Current use of a CGRP-targeting preventive medicine or a beta-blocker
- Opioids or butalbital on five or more days per month for at least 3 months
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Adults, 18-70 years of age at the time of enrollment
- Migraine with aura, migraine without aura, and/or chronic migraine; according to ICHD-3 diagnostic criteria. (Those with daily or continuous headaches are not excluded.)
- Migraine onset prior to 50 years of age
- Migraine present for at least 12 months at the time of enrollment
- At least four "moderate to severe headache days" per month (by patient self-report and then confirmed during four-week pre-randomization headache diary phase) A "moderate to severe headache day" is defined as a day during which there is a headache of moderate to severe intensity that lasts for at least four hours, or a day on which a migraine-specific acute medication is taken to treat headache
- If already taking a migraine preventive treatment, willing to continue with that treatment without dose change during the first 16 weeks of the study, including the 4-week run-in phase and 12-week randomized phase
- Not pregnant or breastfeeding
- Women of childbearing potential must agree to use effective methods of contraception to reduce the risk of pregnancy
- Willingness and ability to provide informed consent
- Willingness and ability to complete all research visits
Who cannot take part
- Currently taking atogepant, propranolol, or topiramate*
- Previously took atogepant, propranolol, or topiramate*
- Current use of a CGRP-targeting preventive medication or beta-blocker
- Migraine preventive treatment has been started or dose has been changed within 12 weeks prior to potential enrollment
- Used opioids or butalbital on five or more days per month on average for at least 3 months prior to enrollment
- Secondary headache disorders (medication overuse headache is not an exclusion)
- Current or past epilepsy
- Severe hepatic impairment
- Moderate or more severe renal impairment * Occasional as needed use of propranolol, currently or in the past, is not an exclusion, such as taking as needed propranolol for treatment of anxiety
- Contraindications to taking atogepant, propranolol, or topiramate
- Unwillingness to take atogepant, topiramate, or propranolol
- Migraine with brainstem aura
- Hemiplegic migraine
- Retinal migraine
- Migraine aura without headache (exclusively)
- Pure menstrual migraine
- Trigeminal autonomic cephalalgias
- Facial neuralgias
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Where in United States
- University of Colorado Anschutz Medical CampusAurora, United StatesContact: Adam AngelichTaking people
- University of Vermont Medical CenterBurlington, United StatesContact: Zoe BrownNot yet recruiting
- Onsite Clinical Solutions BallantyneCharlotte, United StatesContact: Summer EvansTaking people
- Onsite Clinical Solutions MecklenburgCharlotte, United StatesContact: Joseph BoveTaking people
- Onsite Clinical Solutions Park Cedar Dr.Charlotte, United StatesContact: Zoe LandinginTaking people
- Ohio State University Wexner Medical CenterColumbus, United StatesContact: Kemba JohnsonTaking people
- JFK Neuroscience InstituteEdison, United StatesContact: Priyanka Basnet, BSN, RNTaking people
- Northern Arizona HealthcareFlagstaff, United StatesContact: Julie Kenkel, RNTaking people
- Apogee Clinical ResearchHazel Green, United StatesContact: Shelby LessmanNot yet recruiting
- Memorial HealthcareHollywood, United StatesContact: Elisa SerantesTaking people
- Clinical Trials of New EnglandHyde Park, United StatesContact: Kenny CarberryTaking people
- Indiana UniversityIndianapolis, United StatesContact: Jill MazurczykNot yet recruiting
- Mayo Clinic FloridaJacksonville, United StatesContact: Tinsae DanaTaking people
- Nuvance Health InstituteKingston, United StatesContact: Rishitha ThanikondaTaking people
- Clinical Research InstituteLos Angeles, United StatesContact: Ana DuchenkoTaking people
- Keck School of Medicine of USCLos Angeles, United StatesContact: Rama KoppulaTaking people
- Northwell HealthManhasset, United StatesContact: Carmen LimaTaking people
- Marshfield Clinic Research InstituteMarshfield, United StatesContact: Megan JohnsonTaking people
- DHR Health Headache CenterMcAllen, United StatesContact: Leah PicazoTaking people
- Apple Med ResearchMiami, United StatesContact: Carlos M ManzanoTaking people
- University of MiamiMiami, United StatesContact: Lilli RestoTaking people
- The Medical College of WisconsinMilwaukee, United StatesContact: Karen Schmidt, RNTaking people
- West Virginia UniversityMorgantown, United StatesContact: Lauren Chase RN, BSNTaking people
- Vanderbilt Medical CenterNashville, United StatesContact: Jordon WinnTaking people
- Mt Sinai Icahn School of MedicineNew York, United StatesContact: Sarah Kurtz, PA-CTaking people
- Advanced Research Institute OgdenOgden, United StatesContact: Stephanie ChurchTaking people
- Nebraska Medical CenterOmaha, United StatesContact: Jana OckenTaking people
- Neuroscience Research CenterOverland Park, United StatesContact: Amy ReinertTaking people
- Desert Physicians Medical GroupPalm Springs, United StatesContact: Cindy RamirezTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Gina SiermineTaking people
- Mayo Clinic - ArizonaPhoenix, United StatesContact: Dani C Smith, MSTaking people
- The Neurology GroupPomona, United StatesContact: Ikram Rfifa, BSTaking people
- Advanced Research InstitutePortland, United StatesContact: Jessica WeedTaking people
- Brown University HealthProvidence, United StatesContact: Deepica ChaudharyTaking people
- Advanced Research Institute - RenoReno, United StatesContact: Amber ThaxtonTaking people
- Mayo ClinicRochester, United StatesContact: Terrell RiekenTaking people
- Onsite Clinical Solutions SalisburySalisbury, United StatesContact: Dexter PerkinsTaking people
- Washington University St. LouisSt Louis, United StatesContact: Alyssa HiseroteTaking people
- Wake Forest University HealthWinston-Salem, United StatesContact: Lauren MiddletonTaking people
About the trial
What the trial wants to find out
This goal of this study is to compare three medications used for migraine preventive treatment.
Read full original descriptionShow less
This study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others.
Research participants will:
* Be randomly assigned to one of the three medications. * Provide information about their migraine pattern using a daily headache diary and during research visits.
The 3 groups in the trial
- AtogepantExisting treatment, for comparison
Participants who are randomized to this arm will take up to 60mg daily for 12 weeks.
Treatment: Atogepant 60 mg
- PropranololExisting treatment, for comparison
Participants randomized to this arm will take up to 160 mg daily for 12 weeks.
Treatment: Propranolol 160 mg
- TopiramateExisting treatment, for comparison
Participants randomized to this arm will take up to 100 mg daily for 12 weeks .
Treatment: Topiramate 100 mg
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison Study
- Plain-language title
- Comparing atogepant, topiramate and propranolol for preventing migraineGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06972056, who can take part
- Record updated
- 13 November 2026